Saravanan Kokila Krishnamoorthy1, Diego Martin1, Khalil Nabeel Salman1, Bobby Kalb1, John Carew2, Philip Andrew Martin3, Kenneth Kokko4, Christian Larsen5, Thomas Pearson5
1Department of Radiology, Emory University, Atlanta, GA, USA; 2Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, USA; 3University of West Georgia, Carrollton, GA; 4Department of Medicine, Emory University, Atlanta, GA, USA; 5Department of Surgery, Emory University, Atlanta, GA, USA
Retrospective single center study measuring the incidence of Nephrogenic Systemic Fibrosis (NSF) in dialysis patients who were administered either gadodiamide or gadobenate dimeglumine. Mean cumulative dose of gadodiamide was 0.16 mmol/kg in 312 patients and 8 (2.6%) developed NSF. Mean cumulative dose of gadobenate dimeglumine was 0.11 mmol/kg in 603 patients and none developed NSF. The cause for this difference is not determined definitively but our results show that a change to a low dose higher relaxivity gadolinium chelate can significantly reduce NSF incidence and that the incidence in dialysis patients is less than 1 in 603 in our patients.